Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06653829 · ClinicalTrials.gov registry record · NA

NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia

A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by North Shore Therapeutics.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06653829 is a NA study of Schizophrenia and Schizoaffective Disorder that has completed, run by North Shore Therapeutics. The registered enrollment target is 20 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06653829, a NA study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by North Shore Therapeutics.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the feasibility and acceptability of a prototype for NST-SPARK (version 1.5). This is an augmented reality (AR) mobile phone application that uses Recovery-oriented Cognitive Therapy (CT-R) to target negative symptoms of schizophrenia. NST-SPARK uses a game AR activity to recapitulate the beginning activation and engagement phase of each CT-R session as per standardized practices for this therapeutic modality.

Conditions Studied

Schizophrenia Schizoaffective Disorder Negative Symptoms in Schizophrenia

Interventions

  • DEVICE SPARK

Study Locations (1)

Minnesota

  • North Shore Therapeutics, Inc. - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-11-06
Est. Completion 2024-08-31
Phase NA

Sponsor

North Shore Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06653829

The ClinicalTrials.gov registry entry for NCT06653829 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (91% lower). The listed sponsor is North Shore Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which SPARK is the first listed.

NCT06653829 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06653829 about?

NCT06653829 is a clinical study titled "NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia". This study evaluates the feasibility and acceptability of a prototype for NST-SPARK (version 1.5). This is an augmented reality (AR) mobile phone application that uses Recovery-oriented Cognitive Therapy (CT-R) to target negative symptoms of schizophrenia. NST-SPARK uses a game AR activity to recap...

What is the current status of trial NCT06653829?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2023-11-06. Estimated completion is 2024-08-31.

What conditions does trial NCT06653829 study?

This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Negative Symptoms in Schizophrenia.

What interventions are being tested in trial NCT06653829?

The interventions under investigation include: SPARK (DEVICE).

Who is sponsoring clinical trial NCT06653829?

This trial is sponsored by North Shore Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06653829 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Schizoaffective Disorder

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.